8-K: Relay Therapeutics Announces Second Quarter 2024 Financial Results and Pipeline Updates

Relay Therapeutics reported its second quarter 2024 financial results, highlighted by progress in clinical programs and the announcement of new pre-clinical programs.

Summary

• Relay Therapeutics announced its second quarter 2024 financial results, reporting a net loss of $92.2 million, or $0.69 per share.
• The company's cash, cash equivalents, and investments totaled $688.4 million as of June 30, 2024, which is expected to fund operations into the second half of 2026.
• Research and development expenses were $92.0 million for the quarter, an increase from $88.2 million in the same period last year, primarily due to the ReDiscover trial for RLY-2608.
• The company announced three new pre-clinical programs focused on vascular malformations, Fabry disease, and NRAS-specific inhibitors.
• A global clinical trial collaboration with Pfizer was initiated for the combination development of RLY-2608 with fulvestrant and atirmociclib in PI3K-mutated HR+/HER2metastatic breast cancer, with a clinical start planned by the end of 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong cash reserves, new programs, and a key collaboration, but it also acknowledges ongoing losses and risks associated with drug development.

Positives

• The company's net loss decreased compared to the same quarter last year, indicating improved financial performance.
• Relay Therapeutics has a strong cash position of $688.4 million, providing a runway into the second half of 2026.
• The initiation of three new pre-clinical programs diversifies the company's pipeline and targets significant unmet medical needs.
• The collaboration with Pfizer for the RLY-2608 triplet combination expands the potential of the drug in breast cancer treatment.
• The company is making progress in its clinical programs, with multiple data readouts expected later in the year.

Negatives

• The company reported a net loss of $92.2 million for the second quarter of 2024.
• Research and development expenses increased to $92.0 million for the quarter, primarily due to the ReDiscover trial.
• Genentech terminated the collaboration agreement for the development and commercialization of migoprotafib, and the company will not continue its development.

Risks

• The company's financial results are subject to risks associated with global economic uncertainty, geopolitical instability, and public health epidemics.
• There is a risk of delays or pauses in current or planned clinical trials.
• Preliminary results from pre-clinical or clinical trials may not be predictive of future results.
• The company faces risks related to demonstrating the safety and efficacy of its drug candidates.
• There are risks associated with obtaining, maintaining, and protecting intellectual property.

Future Outlook

Relay Therapeutics expects multiple data readouts later this year and plans to expand the RLY-2608 development program. The company also anticipates initiating clinical trials for its new pre-clinical programs in vascular malformations, Fabry disease, and NRAS in 2025. The current cash position is expected to fund operations into the second half of 2026.

Management Comments

• Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics, stated that the company made important progress in advancing clinical programs, positioning them well for multiple data readouts later this year.
• He also expressed excitement about the pre-clinical programs unveiled in June, including the first two genetic disease programs, which will be important in driving continued growth and diversification.

Industry Context

This announcement reflects the ongoing trend in the pharmaceutical industry towards precision medicine and targeted therapies. The collaboration with Pfizer highlights the importance of strategic partnerships in drug development. The focus on genetic diseases and oncology aligns with current research priorities in the biotech sector.

Comparison to Industry Standards

• Relay Therapeutics' cash runway into the second half of 2026 is relatively strong compared to many clinical-stage biotech companies, which often have shorter cash runways.
• The company's focus on novel targets like NRAS and its approach to genetic diseases positions it as a leader in innovative drug discovery, similar to companies like Blueprint Medicines and Agios Pharmaceuticals.
• The collaboration with Pfizer is a significant validation of Relay's technology and approach, similar to other biotech companies that partner with larger pharmaceutical firms to accelerate drug development.
• The reported R&D expenses are typical for a company in clinical development, but the increase highlights the costs associated with advancing multiple programs.

Stakeholder Impact

• Shareholders may view the financial results and pipeline updates positively, especially the strong cash position and new programs.
• Employees may be encouraged by the company's progress and future plans.
• Patients may benefit from the development of new therapies for various diseases.
• The collaboration with Pfizer could lead to increased opportunities for suppliers and partners.

Next Steps

• The company plans to provide a data update for the RLY-2608 doublet in the fourth quarter of 2024.
• Initial safety data for the RLY-2608 + fulvestrant + ribociclib triplet combination is expected in the fourth quarter of 2024.
• The clinical trial for the RLY-2608 + fulvestrant + atirmociclib triplet combination is planned to begin by the end of 2024.
• Clinical trials for vascular malformations are planned to begin in the first quarter of 2025.
• Clinical trials for Fabry disease and NRAS programs are expected to start in the second half of 2025.

Key Dates

Keywords

Relay Therapeutics, RLY-2608, Breast Cancer, PI3K, Vascular Malformations, Fabry Disease, NRAS, Clinical Trials, Precision Medicine, Financial Results